EBV-TCR-T（YT-E001）for Patients With EBV-positive Recurrent or Metastatic NPC

Nasopharyngeal Carcinoma Clinical Trial

Official title:

A Pilot Study of EBV-TCR-T(YT-E001) in NPC Patients

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03648697
• Other study ID #: HXYT-001
• Status: Recruiting
• Phase: Phase 2
• Start date: October 10, 2018
• Est. completion date: October 10, 2021

Study information

• Verified date: August 2020
• Source: Fujian Cancer Hospital
• Contact: JianJi Pan
• Phone: 0591-83660063
• Email: panjianji[@]126.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

TCR-T cell therapy experienced a breakthrough for treating tumors in recent years. Phase I / II trial of NY-ESO-1-specific TCR-T treatment for synovial sarcoma and melanoma conducted by the Rosenberg team at the National Cancer Institute showed that 61% Synovial cell sarcoma and 55% melanoma had therapeutic responses. These and lots of clinical achievements indicate that TCR-T cell therapy can target a variety of tumors including solid tumors without any severe side effects found in CAR-T trials.

Nasopharyngeal carcinoma (NPC), a kinds of head-neck malignant tumor, which used to appear mostly in southern China (especially in Fujian and Guangdong and Guangxi provinces). Most patients with NPC show evidence of infection with the Epstein Barr virus (EBV) before or at the time of their diagnosis. EBV is found in the cancer cells of almost all patients with advanced stage NPC, and play a role in causing and inducing the disease program and development. The cancer cells infected by EBV are able to hide from the body's immune system and escape destruction. We want to see if EBV antigen special T cells (YT-E001) could recognize and kill special parts of EBV infected cells, and finally inhibit the tumor recurrence or metastasis of NPC patients.

This study will focus on the NPC highly expressed EBV antigen such as LMP1, LMP2 and EBNA1，the high affinity TCR target the above EBV antigen were screened from the healthy donor using the sorting and single cell cloning technique. Then, using the lentivirus to transduce the TCR gene to the autologous T cells.

This study will investigate the safety and tolerability of EBV-TCR-T cell therapy in subjects with NPC who had received prior therapy for their disease but their disease has progressed or relapsed.

The chemotherapy we will use for lymphodepletion is a combination of cyclophosphamide and fludarabine. Cyclophosphamide and fludarabine are the chemotherapy agents most commonly used for lymphodepletion in immunotherapy clinical trials.

Description:

This Phase I/II study is designed as single dose pilot trial evaluating the safety and of EBV-TCR-TT cell therapy in subjects with NPC who have received prior therapy for their disease but the disease has progressed or relapsed. Anti-tumor activity and other exploratory objectives will be assessed. Subjects enter from a Screening Protocol and are positive for HLA- A02:01/24:02/11:01, and EBV serum positive. Subjects will receive cytoreductive chemotherapy with cyclophosphamide and fludarabine on days -6 and -4 followed by infusion of dose of about 2×108 EBV-TCR-T(YT-E001).

Subjects will stay in hospital for safety and efficacy assessment daily from T cell infusion (Day 0) through Day 7, and then weekly until week 4 and then at 8 weeks every 8 weeks until progression of their disease or the end or termination of trial.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 20
• Est. completion date: October 10, 2021
• Est. primary completion date: October 8, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. =18 years old;

2. Sign an informed consent before undertaking any trial-related activities;

3. NPC patients diagnosed by licensed pathologist, EBV DNA copy number >500.

4. Received at least one run of standard therapy (surgery, chemo, radiation and targeted therapy) or first line and second line treatment failure;

5. HLA-A*0201/2402/1101;

6. ECOG score 0-2;Life expectancy is longer than 3 months;

7. No Chinese herbal medicine usage within 4 weeks before enrollment;

8. Lab test results meet the following requirements:

White blood cell count=4.0×109/L; ANC=1.5 ×109/L; PLT=100 ×109/L; Hemoglobin=90g/L; Prothrombin time or INR =1.5× normal upper limit, except taking anticoagulant therapy; PTT=1.5× normal upper limit;AST=3×ULN; ALT=3×ULN; ALP=3×ULN; TBIL=1.5×ULN?

9. Levels of calcium, potassium, and magnesium in serum are within the normal range;

10. Pregnancy test is negative for female subjects with reproductive capability before participating the study Female subjects must consent using birth control during the study or prohibit any homo or heterosexual behavior;

11. Can regularly visit the research institutions for tests, evaluations, and monitoring throughout the study period.

Exclusion Criteria:

1. Received major surgery, conventional chemotherapy, large-area radiotherapy, immune therapy or any biological anti-tumor therapy within 4 weeks prior to the study;

2. Allergic to any components of the therapy;

3. Never recovered to <2 grade CTCAE from prior surgery or treatment-related adverse events;

4. With two or other types of primary solid tumors;

5. Poorly managed hypertension (systolic blood pressure >160 mmHg and / or diastolic blood pressure > 90 mmHg) or clinically significant(for example, active) cardiovascular and cerebrovascular diseases such as cerebrovascular incident (within 6 months prior to signing the informed consent), myocardial infarction (within 6 months prior to signing the informed consent), unstable angina, grade II or above heart failure, Congestive, or severe arrhythmia can not be controlled by medication or has a potential impact on the study;

6. With other serious organic disease and/or mental illness;

7. With systemic active infections that need treatments, including active tuberculosis, HIV/HBV/HCV- positive or clinically active hepatitis A, B and C;

8. With autoimmune diseases: such as a history of inflammatory bowel disease (IBD) or other autoimmune diseases determined by the investigator to be unsuitable for the study (e.g. systemic lupus erythematosus (SLE), vasculitis, invasive pulmonary disease);

9. Within 4 weeks prior the infusion, received chronic systemic steroid cortisone, Hydroxyurea, immunomodulatory treatment (for example: Interleukin 2, alpha or gamma interferon, GCSF, cyclosporine etc.);

10. History of organ allografts, autologous / allogeneic stem cell transplantation, and renal replacement therapy;

11. With central nervous system metastasis.

12. With uncontrolled diabetes, pulmonary fibrosis, interstitial lung disease, acute lung disease, or liver failure;

13. Pregnant or lactating female patients;

14. Received concomitant medication prohibited by the protocol;

15. With any medical condition or disease determined by the investigators that may be detrimental to this trial;

Related Conditions & MeSH terms

• Nasopharyngeal Carcinoma

Intervention

Biological:
• EBV-TCR-T (YT-E001) cells
EBV-TCR-T (YT-E001) cells are prepared via lentiviral infection. 6-10 days prior to infusion of TCR-T cells (YT-E001), subjects receive fludarabine at dose 30mg/m2/day for 4 days and cyclophosphamide treatment at dose 30mg/kg/day for 2 days and take a rest for one day before infusion. Patients, who receive an infusion of YT-E001, will remain in the hospital to be monitored for adverse events until they have recovered from the treatment. Patients will have frequent follow-up visit to monitor the persistence of modified T cells and efficacy of the treatment.

Locations

Country	Name	City	State
China	Fujian Cancer Hospital	Fuzhou	Fujian

Sponsors (2)

Lead Sponsor	Collaborator
Fujian Cancer Hospital	China Immunotech (Beijing) Biotechnology Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of participants with adverse events	To evaluate the safety and feasibility of the administration of EBV-TCR transduced T cells(YT-E001) in patients with EBV+ NPC.	60 days
Secondary	Number of participants with clinical responses	To evaluate the efficacy of EBV positive NPC patients treated with EBV antigen specific affinity-enhanced TCR transduced autologous T cell therapy(YT-E001).	1 YEAR